new/era/mabs

Munich, Germany· Est. 2018

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

new/era/mabs is a private, platform-based biotech service provider leveraging its proprietary selmax technology for high-throughput antibody discovery. Its core value proposition is delivering antibody leads four times faster than conventional methods by using immortal antigen-specific cell pools that allow for infinite screening. The company serves research, diagnostic, and therapeutic partners with tailored antibody sets and manufacturing, with notable applications in infectious diseases (e.g., SARS-CoV-2) and neurodegenerative targets. It appears to be in an early-revenue stage, collaborating with academic and industry partners to advance its platform.

OncologyImmunologyInfectious DiseasesNeurodegenerative Diseases

Technology Platform

Proprietary 'selmax' mammalian cell display system for high-throughput antibody discovery. It uses immortal antigen-specific cell pools for infinite screening of secreted, natively formatted antibodies from murine, human, and camelid sources, claiming a 4x faster timeline than conventional methods.

Opportunities

The growing demand for rapid antibody discovery in biopharma and diagnostics, coupled with increased global focus on pandemic preparedness, presents a significant market opportunity.

The unique properties of camelid nanobodies open doors in neurology, imaging, and inhaled therapeutics where conventional antibodies struggle.

Risk Factors

Intense competition from established CROs and platform companies requires clear differentiation.

The service-based model is project-dependent and susceptible to R&D budget fluctuations.

Broad validation of the selmax platform's superiority over industry standards is still ongoing.

Competitive Landscape

new/era/mabs competes with large contract research organizations (CROs) offering antibody services and specialized discovery platforms like AbCellera (microfluidics), Biolojic (AI), and Alpaca (nanobodies). Its key differentiators are the claimed 4x speed advantage, the infinite screening capability of immortal cell pools, and integrated manufacturing.